Neuromod Devices LimitedThursday, 13 April 2023
ByrneWallace LLP advise Neuromod Devices Limited (Neuromod), a medical technology company in connection with a €30 million fundraising to further expand into the US market.
Founded in 2010, Neuromod specialises in non-invasive neuromodulation technologies. The company operates a centre of excellence specialising in neuromodulation and tinnitus in Dublin, offering tinnitus assessments and treatment with its Lenire tinnitus treatment device. Neuromod’s Lenire device has been approved by the Food and Drug Administration (FDA), the US regulator, for the treatment of severe tinnitus in the US market.
The ByrneWallace team who advised on this transaction included Catherine Dowling (Partner, Corporate and Life Sciences), Triona Ryan (Partner, Banking and Finance), Catherine Cusack (Senior Associate, Corporate) and Jane McKay (Associate, Banking and Finance).
For more information on this transaction and to view Neuromod’s press release click here.
Further press coverage: